Use coupon code TOP15 on all courses

Link

Current Affairs

CSIR-IGIB Signs MoU with TATA Sons—To License KNOWHOW for FELUDA

Current Context: CSIR-Institute of Genomics and Integrative Biology (CSIR-IGIB) and TATA Sons signed a MoU for licensing of KNOWHOW for FNCAS9 Editor Linked Uniform Detection Assay (FELUDA) for rapid diagnosis of COVID-19.
CSIR-IGIB Signs MoU with TATA Sons—To License KNOWHOW for FELUDA
  • The MoU is signed to receive the license which includes the transfer of the knowledge for scaling up the KNOWHOW in the form of a kit that can be deployed for COVID-19 testing on ground in May 2020.
  • FELUDA is a complete indigenous scientific invention that has been designed to mitigate the ongoing COVID-19 situation. It is highly affordable, relatively easy to use, and non-dependent on expensive Q-PCR machines.
  • This innovative CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) ‘Feluda’ test uses cutting edge CRISPR technology for detection of genomic sequence of novel coronavirus.
  • CSIR IGIB and TATA Sons will work together to bring FELUDA for widespread use at the earliest.

Question:

Q.1 With whom CSIR-IGIB has signed MoU to license KNOWHOW for FELUDA?
a. Aditya Birla Group
b. Reliance Industries
c. TATA Sons
d. Essar
CSIR-IGIB Signs MoU with TATA Sons—To License KNOWHOW for FELUDA CSIR-IGIB Signs MoU with TATA Sons—To License KNOWHOW for FELUDA Reviewed by Neha Verma on May 07, 2020 Rating: 5

No comments:

Join 8,000+ readers and get free notes in your email